Testing the best radiation dose after R-CHOP for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies how to choose the safest and most effective radiation dose for diffuse large B-cell lymphoma (a type of non-Hodgkin lymphoma) after standard chemotherapy. It may help improve disease control while aiming to limit side effects from radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell lymphoma (DLBCL) confirmed by a tissue (biopsy) diagnosis
- Your doctor expects you can receive radiation therapy after you finish R-CHOP chemotherapy
- You will be able to complete at least 4 cycles of R-CHOP and you do not have worsening lymphoma during chemo
- You are age 18 to 65, and your overall activity level is ECOG 0 to 3 (how able you are to do usual tasks)
- Your lymphoma is stage I to IV (not only a single limited stage)
- Your lymphoma outside lymph nodes is limited: 3 or fewer extranodal sites, and it is not in certain specific locations
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
This trial tests if a new drug combination (R-CMOP) works as well as or better than the usual combination (R-CHOP) for people with a type of lymphoma called DLBCL who haven't had treatment yet.
This study tests a new treatment combination (CD-RCHOP, likely a form of chemotherapy with an antibody) for people with a high-risk type of diffuse large B-cell lymphoma that has certain genetic changes (TP53 mutation and 17p deletion). It aims to see if this approach is safe and effective for this specific group.
This study tests whether using a special blood test (ctDNA) to guide targeted therapy can improve outcomes for people with a type of lymphoma called DLBCL. If you qualify, you may receive a standard chemo-immunotherapy regimen (R-CHOP) possibly combined with other drugs, and your treatment plan may be adjusted based on your ctDNA levels.
Hear when a new NonHodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.